Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
Duloxetine hydrochloride (DH) is a serotonin–norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism. This study aims to develop DH buccoadhesive films to improve its bioavailability. D...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2017.1402216 |
id |
doaj-a4041f920b4147f2977484ad2f50ba77 |
---|---|
record_format |
Article |
spelling |
doaj-a4041f920b4147f2977484ad2f50ba772020-11-25T03:27:17ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642017-01-012411762176910.1080/10717544.2017.14022161402216Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluationAmr Mostafa El Sharawy0Marwa Hassan Shukr1Ahmed Hassen Elshafeey2National Organization for Drug Control and Research (NODCAR)National Organization for Drug Control and Research (NODCAR), Cairo UniversityDuloxetine hydrochloride (DH) is a serotonin–norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism. This study aims to develop DH buccoadhesive films to improve its bioavailability. DH buccoadhesive films were prepared adopting the solvent casting method using hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA). The prepared films were evaluated for weight uniformity, drug content, surface pH, swelling index, mucoadhesion strength and drug release percentages. Accelerated stability and bioavailability studies in healthy human volunteers were also performed for the selected films. Results of the evaluation tests showed that the optimum physicochemical characters were obtained by the films prepared with 2% HPMC using 10% propylene glycol (F2 films). Accelerated stability studies revealed that DH showed proved stability throughout the experiment time. DH bioavailability from F2 films was determined and compared with that of the marketed oral capsules (Cymbalta® 30 mg). The pharmacokinetic results showed that Cmax for F2 was higher than the market product. In addition, ANOVA analysis showed that a Tmax of F2 film was significantly lower, while, the AUC0–72 of F2 was significantly higher than that of Cymbalta capsules. The percentage relative bioavailability of DH from F2 was found to be 296.39%. Therefore, the prepared buccal films offer an alternative route for the administration of DH with the possibility of improving its bioavailability.http://dx.doi.org/10.1080/10717544.2017.1402216buccoadhesive filmsduloxetine hydrochloridemucoadhesiondrug releaseaccelerated stabilitybioavailability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Amr Mostafa El Sharawy Marwa Hassan Shukr Ahmed Hassen Elshafeey |
spellingShingle |
Amr Mostafa El Sharawy Marwa Hassan Shukr Ahmed Hassen Elshafeey Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation Drug Delivery buccoadhesive films duloxetine hydrochloride mucoadhesion drug release accelerated stability bioavailability |
author_facet |
Amr Mostafa El Sharawy Marwa Hassan Shukr Ahmed Hassen Elshafeey |
author_sort |
Amr Mostafa El Sharawy |
title |
Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation |
title_short |
Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation |
title_full |
Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation |
title_fullStr |
Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation |
title_full_unstemmed |
Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation |
title_sort |
formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation |
publisher |
Taylor & Francis Group |
series |
Drug Delivery |
issn |
1071-7544 1521-0464 |
publishDate |
2017-01-01 |
description |
Duloxetine hydrochloride (DH) is a serotonin–norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism. This study aims to develop DH buccoadhesive films to improve its bioavailability. DH buccoadhesive films were prepared adopting the solvent casting method using hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA). The prepared films were evaluated for weight uniformity, drug content, surface pH, swelling index, mucoadhesion strength and drug release percentages. Accelerated stability and bioavailability studies in healthy human volunteers were also performed for the selected films. Results of the evaluation tests showed that the optimum physicochemical characters were obtained by the films prepared with 2% HPMC using 10% propylene glycol (F2 films). Accelerated stability studies revealed that DH showed proved stability throughout the experiment time. DH bioavailability from F2 films was determined and compared with that of the marketed oral capsules (Cymbalta® 30 mg). The pharmacokinetic results showed that Cmax for F2 was higher than the market product. In addition, ANOVA analysis showed that a Tmax of F2 film was significantly lower, while, the AUC0–72 of F2 was significantly higher than that of Cymbalta capsules. The percentage relative bioavailability of DH from F2 was found to be 296.39%. Therefore, the prepared buccal films offer an alternative route for the administration of DH with the possibility of improving its bioavailability. |
topic |
buccoadhesive films duloxetine hydrochloride mucoadhesion drug release accelerated stability bioavailability |
url |
http://dx.doi.org/10.1080/10717544.2017.1402216 |
work_keys_str_mv |
AT amrmostafaelsharawy formulationandoptimizationofduloxetinehydrochloridebuccalfilmsinvitroandinvivoevaluation AT marwahassanshukr formulationandoptimizationofduloxetinehydrochloridebuccalfilmsinvitroandinvivoevaluation AT ahmedhassenelshafeey formulationandoptimizationofduloxetinehydrochloridebuccalfilmsinvitroandinvivoevaluation |
_version_ |
1724588500370587648 |